Ocular involvement
The eye may be involved in leprosy in a number of ways and these are dependent on the immune status of the patient. Direct invasion of the globe by M. leprae occurs in the lepromatous form of the disease; the route of entry is believed to be chiefly bloodborne although some local spread from adjacent structures may occur. Acute inflammatory reactions affecting the facial nerve, cornea and iris are a feature of Type I (reversal) and Type 2 (erythema nodosum leprosum) reactions and may cause severe damage to the eye either directly or indirectly. Ocular complications may also occur indirectly through impairment of lid closure (VII nerve) and corneal anaesthesia (V nerve), and the combination of these two conditions is a potent cause of blindness in all forms of the disease. The eye may also be involved through damage to adnexal tissues and secondary infection is always a risk in a chronically affected eye. It is not surprising that with so many mechanisms of ocular involvement the clinical manifestations of ocular leprosy are diverse, and all forms of the disease may cause complications. Some, however, are more likely than others to give rise to serious visual symptoms, and a useful concept is the identification of 'potentially sight-threatening' (PST) lesions as distinct from those considered only as 'academic' (Lamba et al. 1983 ). The important PST lesions include lagophthalmos, corneal anaesthesia, exposure keratitis, scleritis, staphyloma, acute and chronic iridocyclitis, low intraocular pressure and cataract.
Ocular manifestations
It is beyond the scope of this review to describe the ocular complications of leprosy in detail; the manifestations are extensive and varied and in many cases the pathogenesis is ill understood. The leprosy bacillus has a known affinity for small unmyelinated nerves in the cooler parts of the body, although all forms of neural tissue are damaged in the established disease; hence its attraction to the superficial structures of the face and the anterior part of the eye. It is rare to observe leprotic involvement of ocular tissues posterior to the equator of the eye and blinding lesions are almost exclusively confined to the anterior segment. The commoner manifestations of eye complications in leprosy are summarized in Table 1 . Those lesions considered to be potentially sight-threatening require close supervision and in many instances active therapy.
The common feature of many of these conditions is that they may be prevented by timely interventionnot just by trained ophthalmologists, but by paramedical staff without ophthalmic knowledge in depth who have the ability to examine the anterior segment of the eye and to interpret their findings intelligently. Primary care may be able to prevent much severe visual impairment, but once the condition has advanced to cause structural damage to the cornea, iris or lens, specialized ophthalmic surgery is often necessary. This implies the utilization of trained personnel and equipment and is thus subject to all the logistic and financial problems that beset Third World medicine.
Current therapy
Specific ocular therapy does not exist, and certainly the anti-leprosy drugs that are used systemically have little local application. General ophthalmic measures to suppress acute inflammationsusually local or systemic steroidsplay an important role, as do local antibiotics to counteract secondary infection. Other measures are centred around protection of the globe in patients with facial weakness, and the general care and attention of both patient and leprosy worker in order to eliminate minor injuries and ocular insults that may develop into major problems in eyes that are already compromised.
From the systemic point of view effective chemotherapy of leprosy began in the 1940s with dapsone (di-amino-diphenylsulphone), but it was never applied on a sufficiently large scale to have a significant effect on breaking the chain of transmission in most leprosy-endemic countries, although it was effective in the arrest of leprosy in many hundreds of thousands of patients. In recent years, however, it has become abundantly clear that its use through the decades as monotherapy has resulted in a very large number of dapsone-resistant cases: these have now been identified in most parts of the world, both in treated and untreated patients. More than any other single factor, it was this which prompted the development by the World Health Organization (1982) of recommendations for the use of multiple-drug therapy in all cases of leprosy, using relatively short courses. Paucibacillary (tuberculoid, borderlinetuberculoid and indeterminate) cases receive 6 months' treatment only with daily dapsone (unsupervised) and monthly rifampicin (supervised). All treatment then stops and the patient is kept under observation for a period which ideally should be not less than about 3 years. Multibacillary patients (lepromatous, borderline-lepromatous and mid-borderline) will receive a minimum of 2 years' treatment with three drugs: dapsone daily (unsupervised), rifampicin monthly (supervised), and clofazimine (also called Lamprene and B663) both daily (unsupervised) and monthly (supervised). These regimens have already been established in many leprosy-endemic countries and it can be said that patient acceptability is good and that no unusual or unexpected adverse or toxic effects have been recorded so far. There is even some evidence that attendance rates have improved, possibly because of the use of multiple drugs (one of which, rifampicin, is rapidly-acting and clinically very impressive) and the short periods of treatment. It should be added that although the minimum period of treatment for multibacillary cases is 2 years, treatment should ideally be continued until slit-skin smears from all sites are negative.
Although in vitro culture of M. leprae is still impossible, tremendous progress has been made in the field of in vivo culture with the discovery in 1971 by Kirchheimer & Storrs of the nine-banded armadillo, Dasypus novemcinctus, Linn., as an animal of great susceptibility to inoculation with leprosy bacilli of human origin. Colonies of these animals have been established in America and the United Kingdom, and the enormous yields of bacilli on sacrifice about one year after inoculation have contributed significantly towards the vaccine programme of the Immunology of Leprosy (IMMLEP) branch of the Special Programme for Research and Training in Tropical Diseases, set up by WHO, UNDP and the World Bank in 1974 . Progress in the preparation of an anti-leprosy vaccine from armadillo-derived leprosy bacilli has recently been reviewed by Rees (1983) . Small-scale pre-vaccine studies, using killed vaccine of armadillo origin prepared by the Wellcome Research Laboratories in England, have been designed to establish the safety and optimal doses for sensitization in man; these began in Norway in February 1983 and it is intended to extend them to the United Kingdom and the United States before similar studies are considered in leprosy-endemic countries.
It bears emphasis that work on a vaccine for leprosy is in its early stages. It is considered that its development and full testing may take at least a further 10 years (Noordeen & Sansarricq 1984) and there is thus no doubt that the mainstay of the attack on leprosy must lie in the continued early detection, diagnosis, correct classification and treatment of patients, using multiple-drug therapy for appropriate periods of time. The urgency and importance of the use of multiple drugs in all cases cannot be overstated, if an escalation of drug resistance is to be avoided. The authoritative advice on this subject by WHO and the plans which are currently being made in many parts of the world to implement such therapy have already drawn attention to the paramount importance of upgrading, by a continuous process of training and retraining, the numbers and quality of medical and paramedical staffwho are involved in the diagnosis and treatment of this disease.
